202 related articles for article (PubMed ID: 23039280)
1. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.
Kronenwett R; Bohmann K; Prinzler J; Sinn BV; Haufe F; Roth C; Averdick M; Ropers T; Windbergs C; Brase JC; Weber KE; Fisch K; Müller BM; Schmidt M; Filipits M; Dubsky P; Petry C; Dietel M; Denkert C
BMC Cancer; 2012 Oct; 12():456. PubMed ID: 23039280
[TBL] [Abstract][Full Text] [Related]
2. Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Denkert C; Kronenwett R; Schlake W; Bohmann K; Penzel R; Weber KE; Höfler H; Lehmann U; Schirmacher P; Specht K; Rudas M; Kreipe HH; Schraml P; Schlake G; Bago-Horvath Z; Tiecke F; Varga Z; Moch H; Schmidt M; Prinzler J; Kerjaschki D; Sinn BV; Müller BM; Filipits M; Petry C; Dietel M
Virchows Arch; 2012 Mar; 460(3):251-9. PubMed ID: 22371223
[TBL] [Abstract][Full Text] [Related]
3. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
[TBL] [Abstract][Full Text] [Related]
4. Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer.
Loughman T; Barron S; Wang CA; Dynoodt P; Fender B; Lopez-Ruiz C; Stapleton S; Fabre A; Quinn C; Nodin B; Jirström K; Razmara F; O'Grady A; Baird AM; Gray SG; Freixo A; Moelans CB; van Diest PJ; Duffy MJ; O'Leary D; Crown J; Bracken AP; Gallagher WM
Clin Chem; 2022 Jun; 68(6):837-847. PubMed ID: 35312747
[TBL] [Abstract][Full Text] [Related]
5. Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer.
Poremba C; Uhlendorff J; Pfitzner BM; Hennig G; Bohmann K; Bojar H; Krenn V; Brase JC; Haufe F; Averdick M; Dietel M; Kronenwett R; Denkert C
Virchows Arch; 2014 Oct; 465(4):409-17. PubMed ID: 25218890
[TBL] [Abstract][Full Text] [Related]
6. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
Cronin M; Sangli C; Liu ML; Pho M; Dutta D; Nguyen A; Jeong J; Wu J; Langone KC; Watson D
Clin Chem; 2007 Jun; 53(6):1084-91. PubMed ID: 17463177
[TBL] [Abstract][Full Text] [Related]
7. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.
Nielsen T; Wallden B; Schaper C; Ferree S; Liu S; Gao D; Barry G; Dowidar N; Maysuria M; Storhoff J
BMC Cancer; 2014 Mar; 14():177. PubMed ID: 24625003
[TBL] [Abstract][Full Text] [Related]
8. First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
Lehmann-Che J; Miquel C; Wong J; Callens C; Rouleau E; Quillien V; Lozano N; Cayre A; Lacroix L; Bieche I; Bertheau P; Teixeira L; Penault-Llorca F; Lamy PJ; DE Cremoux P;
Anticancer Res; 2018 May; 38(5):2909-2914. PubMed ID: 29715116
[TBL] [Abstract][Full Text] [Related]
9. Investigation of recurrence prediction ability of EndoPredict
Watanabe A; Tsunashima R; Kato C; Kitano S; Matsumoto S; Sota Y; Morita M; Sakaguchi K; Naoi Y
Breast Cancer; 2024 Jul; 31(4):593-606. PubMed ID: 38587783
[TBL] [Abstract][Full Text] [Related]
10. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
11. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Marín-Aguilera M; Jares P; Sanfeliu E; Villacampa G; Hernández-Lllán E; Martínez-Puchol AI; Shankar S; González-Farré B; Waks AG; Brasó-Maristany F; Pardo F; Manning DK; Abery JA; Curaba J; Moon L; Gordon O; Galván P; Wachirakantapong P; Castillo O; Nee CM; Blasco P; Senevirathne TH; Sirenko V; Martínez-Sáez O; Aguirre A; Krop IE; Li Z; Spellman P; Metzger Filho O; Polyak K; Michaels P; Puig-Butillé JA; Vivancos A; Matito J; Buckingham W; Perou CM; Villagrasa-González P; Prat A; Parker JS; Paré L
ESMO Open; 2024 Mar; 9(3):102903. PubMed ID: 38452436
[TBL] [Abstract][Full Text] [Related]
12. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.
Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA
Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538
[TBL] [Abstract][Full Text] [Related]
13. Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.
Knezevic D; Goddard AD; Natraj N; Cherbavaz DB; Clark-Langone KM; Snable J; Watson D; Falzarano SM; Magi-Galluzzi C; Klein EA; Quale C
BMC Genomics; 2013 Oct; 14():690. PubMed ID: 24103217
[TBL] [Abstract][Full Text] [Related]
14. A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gong G; Kwon MJ; Han J; Lee HJ; Lee SK; Lee JE; Lee SH; Park S; Choi JS; Cho SY; Ahn SH; Lee JW; Cho SR; Moon Y; Nam BH; Nam SJ; Choi YL; Shin YK
Sci Rep; 2017 Mar; 7():45554. PubMed ID: 28350001
[TBL] [Abstract][Full Text] [Related]
15. A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues.
Takano EA; Mikeska T; Dobrovic A; Byrne DJ; Fox SB
BMC Biotechnol; 2010 Dec; 10():89. PubMed ID: 21162754
[TBL] [Abstract][Full Text] [Related]
16. From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Brase JC; Kronenwett R; Petry C; Denkert C; Schmidt M
Microarrays (Basel); 2013 Aug; 2(3):243-64. PubMed ID: 27605191
[TBL] [Abstract][Full Text] [Related]
17. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.
Bergqvist J; Ohd JF; Smeds J; Klaar S; Isola J; Nordgren H; Elmberger GP; Hellborg H; Bjohle J; Borg AL; Skoog L; Bergh J
Ann Oncol; 2007 May; 18(5):845-50. PubMed ID: 17351254
[TBL] [Abstract][Full Text] [Related]
18. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens.
Sadi AM; Wang DY; Youngson BJ; Miller N; Boerner S; Done SJ; Leong WL
BMC Cancer; 2011 Jun; 11():253:1-13. PubMed ID: 21679412
[TBL] [Abstract][Full Text] [Related]
20. Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues.
Sánchez-Navarro I; Gámez-Pozo A; González-Barón M; Pinto-Marín A; Hardisson D; López R; Madero R; Cejas P; Mendiola M; Espinosa E; Vara JA
Biotechniques; 2010 May; 48(5):389-97. PubMed ID: 20569212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
